论文部分内容阅读
芬戈莫德(fingolimod,FTY-720)最初由日本Mitsubishi制药公司研制,后期全球经营权转让给瑞士Novartis制药公司,并于2010年9月21日获得美国FDA批准上市,成为首个可经口给药的用于治疗复发-缓解型
Fingolimod (FTY-720) was originally developed by Japan’s Mitsubishi Pharmaceuticals. The latter part of the global franchise was transferred to Novartis Pharmaceuticals Switzerland and approved by the US FDA on September 21, 2010, making it the first oral Administered for the treatment of relapsing - remission type